Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

NCT ID: NCT01710176

Last Updated: 2025-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 550 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-06-01
• Study Completion Date: 2024-06-30

Brief Summary

This is a randomized Phase III clinical trial in the setting of localized high-risk soft tissue sarcomas (STS). This study will compare a standard neoadjuvant chemotherapy with epirubicin plus ifosfamide versus a histology-driven chemotherapy, i.e. a chemotherapy tailored to the specific histology within the family of adult STS. Chemotherapy will be administered for 3 cycles. There will be five histological groups (representing 80% of STS), as follows: leiomyosarcoma, myxoid liposarcoma with hypercellularity (round cell MLPS), synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma. The histology-driven chemotherapy for these groups will be, respectively, gemcitabine plus dacarbazine, trabectedin, high-dose ifosfamide, ifosfamide plus etoposide, gemcitabine plus docetaxel. Other histological groups will also be included and registered, but treated only by standard chemotherapy. Patients who have already undergone definitive surgery will receive treatment post-operatively and patients needing a re-excision after inadequate surgery will be treated as patients in the two groups, but of course will not be evaluable for response. A centralized pathological review will be performed. Radiological response will be evaluated according to RECIST and to Choi criteria. Pathological response will also be recorded.

The endpoint will be disease-free survival (DFS) and, secondarily, overall survival (OS) of patients receiving standard chemotherapy versus those receiving histotype-tailored chemotherapy. Additional aims will be to compare the probability of response of standard vs histotype-tailored chemotherapy and to determine the radiological and pathological response with standard chemotherapy vs tailored chemotherapy in each different histological group. Another aim will be to validate the response (both radiological and pathological) to preoperative chemotherapy as a surrogate endpoint for DFS and OS.

Three hundred patients will be randomized over a 3-years period, from a pool of 400-450 registered patients.

Translational research will be performed. Areas of research will include identification and validation of the potential predictive markers for each histological subgroups.

The study is designed to verify the statistical hypothesis that histotype-tailored approach is associated, overall, with a 30% reduction in the hazard of relapse. However, in each different histological group, the effect of histotype-tailored chemotherapy, as compared to standard chemotherapy, can be different. To address this weakness an orthogonal study of response to chemotherapy as a surrogate of DFS and OS has been introduced into the trial. This study intends to extensively investigate the response (radiological and pathological) to preoperative chemotherapy and to validate it as a surrogate endpoint by showing that it correlates with disease free survival and overall survival.

Conditions

Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

standard chemotherapy with full-dose epirubicin + ifosfamide

Standard arm foresees 3 cycles of preoperative chemotherapy, each cycle will be repeated every 21 days and includes: epirubicin 60 mg/m2/day, short infusion, days 1 and 2; ifosfamide 3 g/m2/day, days 1, 2, 3

Group Type: ACTIVE_COMPARATOR

epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)

Intervention Type: DRUG

histotype-tailored chemotherapy according to the histotype

gemcitabine+docetaxel for undifferentiated pleomorphic sarcoma, trabectedin for myxoid liposarcoma with hypercellularity, ifosfamide for synovial sarcoma, ifosfamide+etoposide for malignant peripheral nerve sheath tumor, gemcitabine+dacarbazine for leiomyosarcoma

Group Type: EXPERIMENTAL

gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)

Intervention Type: DRUG

trabectedin 1.3 mg/m2

Intervention Type: DRUG

high-dose ifosfamide 14 g/m2, given in in 14 days

Intervention Type: DRUG

etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)

Intervention Type: DRUG

gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)

Intervention Type: DRUG

Interventions

epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)

Intervention Type: DRUG

gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)

Intervention Type: DRUG

trabectedin 1.3 mg/m2

Intervention Type: DRUG

high-dose ifosfamide 14 g/m2, given in in 14 days

Intervention Type: DRUG

etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)

Intervention Type: DRUG

gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Soft tissue sarcoma of adults, primary or locally recurrent, with spindle-cell or pleomorphic histology, belonging to one of the following for the randomization (Group1):

myxoid-Round Cell liposarcoma (cellular component >5 %), leiomyosarcoma, synovial sarcoma, malignant peripheral nerve sheat tumor, undifferentiated pleomorphic sarcoma (ex Malignant fibrous histiocytoma)

Or belonging to one of the following for the registration (Group 2):

myxofibrosarcoma, unclassified Spindle Cell, pleomorphic liposarcoma, pleomorphic rabdomiosarcoma Or belonging to either group but not being evaluable for response (re-excision after previous inadequate resection or primary definitive surgery) (Group3).

The histological diagnosis must be made according to the WHO criteria and will have to be centrally reviewed before randomization.

2. High malignancy grade: grade 3 of 3, according to Coindre, or grade 2 at biopsy with a radiological evidence of more than 50% of necrosis in the tumor mass.

3. Deep seated extremities, girdles and/or superficial trunk (thoracic or abdominal wall)lesion.

4. Size of primary tumor (visible or previously inadequately resected) >5 cm at instrumental staging (CT, MRI), or locally recurrent of any size.

5. Age > 18 years.

6. ECOG performance status <1.

7. Adequate bone marrow function:

WBC >3.500/mm3 neutrophil >1.500/mm3 platelets >150.000/mm3 hemoglobin >11 g%.

8. Adequate renal (creatinine <1.3 mg%), and hepatic function (bilirubin <1.5 mg% and transaminases <2 x n.v. If ALP > 2.5 x ULN, ALP LF and/or GGT < ULN).

9. Adequate cardiac function (FE >50%).

10. Signed informed consent.

11. Complete compliance of the participating center with the protocol requirements.

5. Prior CT and/or RT.

6. Serious psychiatric disease that precludes informed consent or limits compliance.

7. Medical disease limiting survival to less than two years, limiting compliance or which in the physician's opinion might interfere significantly with the toxicity of the treatments.

8. Cardiovascular diseases resulting in a New York Heart Association Functional Status > 2.

9. Uncontrolled bacterial, viral or fungal infection.

10. Impossibility of ensuring adequate follow-up.

11. Failure to comply with the requirements of the present protocol leading to exclusion of the participating center.

Exclusion Criteria

1. Pregnancy or lactation.

2. Distant metastasis.

3. Other malignancies within past 5 years, with the exception of carcinoma in situ of cervix and basocellular skin cancers treated with eradicating intent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

French Sarcoma Group

OTHER

Sponsor Role: collaborator

Grupo Espanol de Investigacion en Sarcomas

OTHER

Sponsor Role: collaborator

Italian Sarcoma Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -

Candiolo, TO, Italy

Irccs Centro Di Riferimento Oncologico (Cro) -

Aviano (PN), , Italy

Irccs Istituto Ortopedico Rizzoli (Ior) -

Bologna, , Italy

Pres.Ospedal.Spedali Civili Brescia -

Brescia, , Italy

Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori -

Meldola (FC), , Italy

Irccs Istituto Europeo Di Oncologia (Ieo) -

Milan, , Italy

Irccs Istituto Nazionale Dei Tumori (Int)

Milan, , Italy

Irccs Istituto Nazionale Tumori Fondazione Pascale -

Napoli, , Italy

Irccs Istituto Oncologico Veneto (Iov)

Padua, , Italy

Irccs Istituto Regina Elena (Ifo)

Roma, , Italy

Irccs Istituto Clinico Humanitas -

Rozzano (MI), , Italy

Presidio Sanitario Gradenigo Di Torino

Torino, , Italy

Hospital Vall D'Hebron

Barcelona, , Spain

Hospital Clínico de Malaga

Málaga, , Spain

Hospital Son Espases

Palma de Mallorca, , Spain

Countries

Italy; Spain

References

Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Fontana V, Donati DM, Palassini E, Sanfilippo R, Bianchi G, Bertuzzi A, Morosi C, Pasquali S, Stacchiotti S, Bague S, Coindre JM, Miceli R, Dei Tos AP, Casali PG. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). J Clin Oncol. 2024 Mar 10;42(8):898-906. doi: 10.1200/JCO.23.00908. Epub 2024 Jan 17.

Reference Type: DERIVED

PMID: 38232337 (View on PubMed)

Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bague S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18.

Reference Type: DERIVED

PMID: 32421444 (View on PubMed)

Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bague S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9.

Reference Type: DERIVED

PMID: 28499583 (View on PubMed)

Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol. 2016 Dec;27(12):2283-2288. doi: 10.1093/annonc/mdw430. Epub 2016 Oct 11.

Reference Type: DERIVED

PMID: 27733375 (View on PubMed)

Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG, Gronchi A. Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Espanol de Investigacion en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. J Clin Oncol. 2015 Nov 1;33(31):3628-34. doi: 10.1200/JCO.2015.62.9394. Epub 2015 Sep 8.

Reference Type: DERIVED

PMID: 26351345 (View on PubMed)

Other Identifiers

ISG-STS 10-01

Identifier Type: -

Identifier Source: org_study_id